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Because of the economic growth and changes in lifestyle, metabolic diseases have become a major public health
problem, which impose heavy economic burdens on individuals, families and health systems. However, its precise
mediators and mechanisms remain to be fully understood. Clinical translational medicine (CTM) is an emerging area
comprising multidisciplinary research from basic science to medical applications and as a new tool to improve
human health by reducing disease incidence, morbidity and mortality. It can bridge knowledge of metabolic
diseases processes, gained by in vitro and experimental animal models, with the disease pathways found in
humans, further to identify their susceptibility genes and enable patients to achieve personalized medicament
treatment. Thus, we have the reasons to believe that CTM will play even more roles in the development of new
diagnostics, therapies, healthcare, and policies and the Sino-American Symposium on Clinical and Translational
Medicine (SAS-CTM) will become a more and more important platform for exchanging ideas on clinical and
translational research and entails a close collaboration among hospital, academia and industry.
Keywords: Metabolic diseases; Clinical translational medicine; Hepatotoxicity; Colorectal cancer; Obesity; Type 2
diabetes mellitus; microRNAsIntroduction
Lifestyle changes, such as decreased physical activities,
increased excessive caloric intake, or sedentary behavior,
all contribute to the progression of metabolic diseases,
such as diabetes, obesity, or atherosclerosis, at an alarm-
ing rate and have become a major public health problem
[1,2]. The potential correlation between metabolic dis-
eases and cancer attracts more attention from scientific
societies. CTM has been suggested as an emerging area
comprising multidisciplinary research transforms and
scientific discoveries and as a new tool to improve
human health by reducing disease incidence, morbidity
and mortality. Indeed, to improve health, findings from
basic research studies must be translated into practical
applications. Translational research transforms scientific* Correspondence: chenchengshui@126.com
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in any medium, provided the original work is pdiscoveries found in the laboratory into ways to prevent,
diagnosis or treat disease [3]. However, precise media-
tors and mechanisms need to be further clarified [4].
There is still great variability to the response to treat-
ment of metabolic diseases, due to a number of factors,
e.g. genetics, environment, and behavior [5]. It is also
important for clinical and translational scientists to con-
sider how to translate the individual therapy into public
health models for disease prevention or treatment in a
low-resource setting. The SAS-CTM provides one of
the highest and most influential platforms to obtain the
latest development and explore new opportunities in
international collaborations for metabolic diseases.Review
Translational research in hepatotoxicity
Hepatotoxicity (hepatic toxicity) implies chemical-driven
liver damage. The liver has a central function in trans-
forming and clearing chemicals but it is susceptible topen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Shi et al. Clinical and Translational Medicine 2014, 3:2 Page 2 of 6
http://www.clintransmed.com/content/3/1/2the toxicity from these agents. when taken Certain medi-
cinal agents in overdoses, may injure the organ. Drug-
induced liver injury (DILI) limits the development
and application of many therapeutic compounds and
presents major challenges to the pharmaceutical industry
and clinical medicine [6]. It is a major safety concern in
drug development and clinical pharmacotherapy. The
most problematic type of DILI is “idiosyncratic”. This
means that only a very small fraction of treated patients
are susceptible to DILI, e.g. Carbamazepine (CBZ) a widely
used anti-epileptic agent, is generally well tolerated-only a
small number of patients prescribed CBZ develop severe
hepatitis [7]. Idiosyncratic DILI is a complex disorder that
is difficult to predict, diagnose and treat [8,9]. Underlying
metabolic disorders have been suggested as being a predis-
posing factor for DILI. Prof. Paul B. Watkins, University of
North Carolina-Chapel Hill, NC, explained the role of
CTM in DILI with a special statement on Understanding
hepatotoxicity – From patients to mice to computer. In
addition to genetic studies of patients who have experi-
enced DILI from US Drug-Induced Liver Injury Network
(DILIN), they are partnering with Cellular Dynamics Inter-
national to reprogram induced pleuripotent stem cells from
DILIN subjects and are also co-operating with the Shanghai
Centers for Disease Control to prospectively collect a var-
iety of bio-specimens as part of a larger biomarker discov-
ery initiative.
DILI remains the major adverse drug event that leads
to termination of clinical development programs and
regulatory actions including failure for marketing ap-
proval, restricted indications, and withdrawal from the
marketplace. There are more and more preclinical models
for its study. Reliable preclinical testing will probably not
be developed until there is greater understanding of the
mechanisms underlying DILI. Prof. Watkins et al. are using
panels of inbred mice to mimic patient population genetic
diversity and to identify genes and pathways that may
underlie DILI susceptibility in patients. As a result, the
inbred mouse panel approach successfully identified an
unsuspected genetic factor underlying susceptibility to
acetaminophen (paracetamol) hepatotoxicity in humans.
Finally, Prof. Watkins demonstrated that they have estab-
lished the DILIsim Initiative, which is a public-private
partnership that is building a computer model to synthesize
the rapidly accumulating data with the goal of predicting
DILI liability in drug candidates.
Translational research in human colorectal cancer
Colorectal cancer is an important cause of mortality in
our society. The progression of this disease from the
normal colonic-epithelium to the malignant-phenotype
is occurs with numerous genetic and epigenetic alter-
ations. Compelling experimental and omics researches,
indicates that nutrition and diet are important keys inthe modulation of colorectal cancer [10]. In order to
sustain higher proliferative rates and resist some cell
death signals, tumor cells exhibit distinct metabolic phe-
notypes to alter the flux along key metabolic pathways,
such as glycolysis and glutaminolysis [10,11]. When used
as a translational research tool, metabolomics is the up-
coming new science in the omics field with the potential
to further increment our knowledge of cancer biology
[12]. Cancer metabolomics research aims at evaluating
and predicting pathophysiological changes of cancer
patients by investigating metabolic signatures in body
fluids or tissues, which are influenced by genetics, epi-
genetics, environmental exposures, diet, and behavior.
Prof. Wei Jia, University of North Carolina at Greens-
boro, described their studies with mass spectrometry
based on metabolomic profiling of serum, urine and tis-
sue samples from colorectal cancer (CRC) patients enti-
tled “Metabolic profiling of human colorectal cancer: A
Top-down Approach to Translational Cancer Research”.
A particular advantage of metabolomics is that it repre-
sents a top-down tactic in that all of the molecules
detected are interrogated, providing a global picture of dy-
namic metabolic changes involving key markers and path-
ways those were not already associated with carcinogenesis.
Metabolomics is a powerful tool for biomarker discovery
and the investigation of pathological processes, phenotypic
variations, and treatment effects. The metabolic profile of
CRC involves several significantly altered metabolic path-
ways, including increased glycolysis and an impaired tri-
carboxylic acid cycle, dysregulations of glutaminolysis and
down-regulated urea cycle. In addition, dysregulation of
amino acids and nucleotides, carnitine family, choline fam-
ily, and gut microbial co-metabolites were also observed.
Prof. Jia demonstrated their experimental results and em-
phasized the potential for the metabolomic approach for
having a multitude of use in oncology, including the early
detection and diagnosis of cancer and as both a predictive
and pharmacodynamic marker of therapeutic effect.
Translational research in obesity
Obesity, worldwide, is becoming a major problem with
an increased risk of several common diseases including
diabetes, cardiovascular disease, and cancer [13,14]. It is
generally accepted that hypoxia is related to sleep apnea
in obesity. This concept has changed since the finding of
hypoxia response in adipose tissue of obese mice in
2005. Adipose tissue is a key endocrine organ as it releases
multiple bioactive substances, known as adipose-derived
secreted factors or adipokines, that have pro-inflammatory
or anti-inflammatory activities [15]. Recent studies consist-
ently support a hypoxia response in the adipose tissue in
obese animals. The observations have led to the formation
of an exciting concept: adipose tissue hypoxia (ATH), in the
understanding of major disorders associated with obesity
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dressed the Hypoxia in Obesity-From Bench to Bedside.
The ATH provides a unified answer to all of the patho-
logical changes in the adipose tissue under obesity, such
as chronic inflammation, endoplasmic reticulum stress, lep-
tin expression, adiponectin reduction, adipocyte death and
elevated lipolysis.
The ATH suggests that capillary dysfunction occurs
during expansion of adipose tissue, and leads to reduc-
tion in adipose blood supply, which is responsible for
hypoxia in obesity. The adipose tissue dysfunction is a
result of local vascular failure. In addition, it stimulates
the inflammatory response in favor of the adipose tissue
remodeling and energy expenditure to fight against
obesity. These new insights into the ATH suggest that
the hypoxia response also has a beneficial effect in the
body. Prof. Ye emphasized that sleep apnea is a protect-
ive mechanism in feedback to obesity by using the hyp-
oxia response to trigger the onset of multiple protection
mechanisms in the body.
Many millions of years of evolution have passed from
ape to human. We found that humans began a slow but
gradual manifestation of the state of obesity. But what
are the reasons that lead to obesity pathogenesis? Is it
the result of evolution? Or the unhealthy life style? With
these questions, Prof. Guang Ning, The Vice President of
Ruijin Hospital Affiliated Shanghai JiaoTong University
School of Medicine, retrospected the obesity prevalence
and its relationship with economic development and life-
style transition in China entitled “Translational Medicine in
China: Improving Public Health” that consider obesity as a
complex disease, resulting from both external and internal
causes. The external causes usually mean environmental
factors including socio-economy, life style, nutrition and
others. The internal causes refer to genetic factors. Further-
more, the prevalence of diabetes gradually increased with
the development of obesity. Prof. Ning suggested that the
translation of this view into clinical setting, will provide
clinical evidence for the interaction between obesity and
diabetes.Translational research in type 2 diabetes mellitus
The incidence of type 2 diabetes mellitus (T2DM) is in-
creasing at an alarming rate, in part due to the dramatic
rise in obesity in developed countries, as T2DM is a co-
morbidity frequently seen in obese subjects. Because not
all obese patients develop T2DM and not all subjects
suffering from T2DM are obese or overweight [17], it is
of vast interest to understand the mechanisms under-
lying the association between these two entities in order
to predict which patients are at higher risk for develop-
ing this disease, and possibly for the development of pre-
ventative therapies.Because of the economic growth and changes in life-
style, diabetes has become an important public health
problem. e.g. a national study from 2007 to 2008 showed
that the age-standardized prevalences of diabetes and
prediabetes were 9.7% and 15.5%, respectively, account-
ing for 92.4 million adults with diabetes and 148.2 mil-
lion adults with prediabetes [1]. Compared with 1979,
the prevalence of diabetes increased by 8 times in 2008.
Alarmingly, the rapid rise in obesity and T2DM in all
age groups might result in a substantial increase in
prevalence of diabetes-related cognitive dysfunction [17].
T2DM is influenced by the environmental factors and
genetic factors [18]. According to the heterogeneity in
environmental factors as well as genetic background, the
susceptibility of T2DM in different ethnic populations is
totally different, with low susceptibility in Caucasians,
while little susceptibility in Chinese Hans. Prof. Weiping
Jia, President of Shanghai Jiao Tong University Affiliated
Sixth People’s Hospital, emphasized the importance of
Susceptible genes of type 2 diabetes and their disease pre-
dictive power in Chinese population.
The recent success of genetics has identified 50 suscep-
tible genes of T2DM in Caucasians by biology candidate
study, linkage study and also genome-wide association
study, among which some loci such as KCNJ11, TCF7L2,
TCF2 genes have been replicated successfully in our
Chinese Han population with the odds ratio ranging from
1.14-1.31. Besides, by replicating the susceptible genes
specific for the East Asian, 6 loci showed significance in our
Chinese samples, with KCNQ1 showing the strongest
association with T2DM [19]. However, although nearly 50
susceptible genes for T2DM were identified so far, the pre-
diction effects were still limited. Thus, Prof. Jia suggested
that the utility of both genetic and environmental factors
will be worthwhile exploring in the disease prediction.
In addition, genetic factors involved in drug absorp-
tion, distribution, metabolism and target attribute to
differences between patients and affect clinical anti-diabetic
treatments. The identification of genetic markers related to
drug reaction can help physicians with the decisions of (a)
drug selection, (b) dose titration, (c) treatment duration,
and (d) avoidance of advert drug reactions. These advances
in understanding the genetics of T2DM will lead to the de-
velopment of new therapeutic and preventive strategies and
individualized medicine. Associate Prof. Cheng Hu, Shang-
hai Jiao Tong University Affiliated Sixth People’s Hospital,
focused on the effects of susceptibility genes for T2DM on
anti-drugs’ efficacy and addressed Pharmacogenomics in
type 2 diabetes management: towards personalized medi-
cine. It had been already suggested that effects of some
genetic variants on the response to repaglinide and
rosiglitazone affect either its pharmacokinetics or
pharmacodynamics. In spite of all these advances in
the field of pharmacodynamics of T2DM, the pace of
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Associate Prof. Hu advised that more research, espe-
cially randomized clinical trials into practical utility,
should be conducted.
Translational research in microRNA
MicroRNAs (MiRNAs) are a class of small non-coding
RNAs that negatively regulate gene expression at the
post-transcriptional level by binding to homologous re-
gions in the target mRNAs blocking translation and/or
inducing mRNAs degradation [20]. Dysregulated expres-
sion of miRNAs in various tissues has been associated
with a variety of diseases, including cancer [21,22]. For
example, one of the first characterized miRNA families
relevant in carcinogenesis was the miR-17-92 cluster
which is involved in immune system regulation and is
up-regulated in lung cancer [23]. The levels of miRNAs
in serum are stable, reproducible, and consistent among
individuals of the same species. Prof. Chenyu Zhang, Life
Science, Nanjing University, introduced their early experi-
mental work about sequencing all serum miRNAs of
healthy Chinese subjects and identifying specific expres-
sion patterns of serum miRNAs for lung cancer, colorectal
cancer and diabetes with a special statement on Circulat-
ing MicroRNA, Secreted MicroRNA and Exogenous Plant
MicroRNA. Through these analyses, we conclude thatFigure 1 CTM as a new clinical tool and application of personalized m
phenotype, then explores particular signaling pathway characterized by molecu
readouts of cellular profiling assays, further to identify their susceptibility genes aserum miRNAs can serve as potential biomarkers for the
detection of various cancers and other diseases.
Here, Prof. Zhang also report that secreted miRNAs
can serve as novel signaling molecules mediating inter-
cellular communication. They found that THP-1 cells
can actively and selectively package miR-150 into micro-
vesicles and secrete them into circulation. Microvesicles
then can deliver miR-150 into human microvascular
endothelial cells, resulting in suppression of c-Myb (a
known target gene for miR-150) in recipient cells and
enhanced migration capacity. These results demon-
strate that cells actively secreted miRNAs and deliver
them into specific recipient cells where the exogenous
miRNAs can regulate target gene expression and re-
cipient cell function.
A grand challenge about multiple metabolic controls
Metabolic diseases and their complications are impos-
ing heavy economic burdens on individuals, families,
health systems and countries including China [24].
Take diabetes as an example: the clinical characteristics
of T2DM appear several years after the onset of this
process during which time the person is asymptomatic.
Once T2DM clearly appears, it is not possible to re-
verse the disease progression. Despite this, it is pos-
sible and of utmost importance to properly controledicament treatment. CTM focus on the metabolic disease related
lar targets or transcriptional events through biochemical or cellular
nd enable patients to achieve a personalized medicines treatment.
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lowing clinical advise. Thus, early detection of, or even
more importantly, the possibility to avoid, T2DM onset
would be of extreme benefit. Moreover, in diabetic pa-
tients, the prevalence of diabetic retinopathy was
16.9%. The prevalence of albuminuria and peripheral
vascular disease was 25.7% and nearly 15% [25,26]. All
these chronic complications may cause serious conse-
quences, including blindness, renal dysfunction, strokes,
myocardial infarction and amputation. Since 2003, with the
support of Department of Disease Control of the Chinese
Ministry of Health, Chinese Diabetes Society of the Chinese
Medical Association published the Guideline for Diabetes
Prevention and Treatment in Chinese. The guideline has
been revised twice according to the evidence-based clinical
trials. Prof. Yuqian Bao, Shanghai Jiao Tong University
Affiliated Sixth People’s Hospital, described a Hospital-
Community Diabetes Integrated Management entitled
“A grand challenge about multiple metabolic control:
health care delivery from tertiary level hospital to
primary care health center” to increase “three rates”
which include glucose control rate, screening rate of
chronic complication and awareness rate of diabetes
knowledge in Shanghai communities.
The Hospital-Community Diabetes Integrated Manage-
ment established collaboration between urban hospitals
(tertiary hospital) and community health services. The hos-
pital and community health services have their own re-
sponsibilities. Tertiary hospital was in charge of training,
establishing management guideline and providing a referral
platform. The community health services center was in
charge of organizing a management team and medical re-
cords, implementing the management according to the
guideline and starting dual referral. Prof. Bao showed that
up till now nearly 9,000 high risk individuals completed
diabetes screening in 3 communities. And more than
5,000 medical records were managed by the commu-
nity health services. The “three rates” improved signifi-
cantly as consequence.
Conclusions
In conclusion, metabolic diseases, a public health problem,
the medical management of them has become increasingly
complex, and its complications remain a great burden to
individual patients and the larger society. Various mediators
and mechanisms linking to metabolic diseases have been
postulated. Modern health care is currently and globally
undergoing a big revolution, where innovative therapies
and novel technology advancements are having profound
impacts on improving patient care and managing costs.
One of the cornerstone with health care with great impact
on metabolic diseases is the increasing number of personal-
ized medicines being introduced into market. Much clinical
interest lies in drug metabolism and the opportunity toimprove prescribing efficacy and safety. CTM as a new clin-
ical tool and application of clinical medicine and public
health that faces great challenges and opportunities. It can
bridge knowledge of metabolic diseases processes, gained
by in vitro and experimental animal models, with the dis-
ease pathways found in humans, further to identify their
susceptibility genes and enable patients to achieve personal-
ized medicament treatment (Figure 1). In this way we have
reason to believe that CTM will play even more roles in
novel diagnostics/prognostics and therapies for clinical use,
post-genomic knowledge and experience, and/or new disci-
plines that reflect additional levels of complexity. And SAS-
CTM will become a more and more important platform
for exchanging ideas on clinical and translational research
and meet the demands of maintaining or expanding the
biomedical workforce and education programs that attract
and retain young people in translational and biomedical
sciences.
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